- Capmatinib
-
- $0.00 / 1g
-
2024-03-12
- CAS:1029712-80-8
- Min. Order: 1g
- Purity: 98% HPLC
- Supply Ability: 1KG
- Capmatinib
-
- $0.00 / 1kg
-
2023-12-21
- CAS:1029712-80-8
- Min. Order: 1kg
- Purity: 99%，single impurity＜0.1
- Supply Ability: 1 ton
- Capmatinib
-
- $0.00 / 25kg
-
2023-12-01
- CAS:1029712-80-8
- Min. Order: 1kg
- Purity: ＞99% by HPLC
- Supply Ability: 10kg/month
|
| Product Name: | Capmatinib | | Synonyms: | INCB028060;CapMatinib (INCB28060);CapMatinib;NC280 BenzaMide,2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-;NVP-INC280;2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide Capmatinib (INCB28060);INCB28060, INC280;BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-
INCB28060 | | CAS: | 1029712-80-8 | | MF: | C23H17FN6O | | MW: | 412.42 | | EINECS: | 813-241-9 | | Product Categories: | Inhibitors;API | | Mol File: | 1029712-80-8.mol |  |
| | Capmatinib Chemical Properties |
| Melting point | >250°C (dec.) | | density | 1.40 | | vapor pressure | 0-0Pa at 20-25℃ | | storage temp. | -20°C Freezer, Under inert atmosphere | | solubility | DMSO (Slightly), Methanol (Slightly) | | pka | 13.82±0.46(Predicted) | | form | Solid | | color | Pale Yellow to Light Yellow | | InChI | InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31) | | InChIKey | LIOLIMKSCNQPLV-UHFFFAOYSA-N | | SMILES | C(NC)(=O)C1=CC=C(C2=NN3C(CC4=CC=C5C(=C4)C=CC=N5)=CN=C3N=C2)C=C1F | | LogP | 1.6-2.2 at 35℃ and pH7-9 |
| | Capmatinib Usage And Synthesis |
| MET small molecule inhibitor | Capmatinib(Synonyms: INC280; INCB28060) is a competitive inhibitor with very potent and selective activity against MET compared to other kinases. It has been shown in vitro that cell lines made resistant to erlotinib, an EGFR inhibitor, could be resensitized after capmatinib treatment. Results from a phase Ib/II study of patients with EGFR-mutated, MET-dysregulated NSCLC have shown promising responses to a combination of capmatinib and gefitinib (EGFR TKI) following disease progression from an only EGFR TKI treatment regimen. Recommended phase II dose was determined to be capmatinib 400 mg twice/day and gefitinib 250 mg once/day. Most common adverse events were nausea, peripheral edema, decreased appetite, rash, and increased amylase and lipase levels. | | Originator | Novartis
| | Description | INCB 28060 is an inhibitor of heptatocyte growth factor receptor (HGFR, also known as c-Met), potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activity in cells (IC50 values range from 0.3 to 1.1 nM). It blocks cell proliferation and migration or induces apoptosis in different types of cancer cells. INCB 28060 is orally bioavailable and inhibits the growth of HGFR-dependent tumors in mice. It also improves efficacy of gemcitabine in a mouse pancreatic cancer model and reduces migration and adhesion in ovarian cancer cell models. | | Description | Capmatinib is a competitive inhibitor with very potent and selective activity against MET compared to other kinases. | | Uses | 2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide is used in the preparation of a combination formulation with allosteric SHP2 inhibitor TNO155. Used in treatment of non-small cell lung cancer with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping). | | Side effects | Most common adverse events were nausea, peripheral edema, decreased appetite, rash, and increased amylase and lipase levels. | | in vitro | It has been shown in vitro that cell lines made resistant to erlotinib, an EGFR inhibitor, could be resensitized after capmatinib treatment. Results from a phase Ib/II study of patients with EGFR-mutated, MET-dysregulated NSCLC have shown promising responses to a combination of capmatinib and gefitinib (EGFR TKI) following disease progression from an only EGFR TKI treatment regimen. Recommended phase II dose was determined to be capmatinib 400 mg twice/day and gefitinib 250 mg once/day. | | target | c-MET | | references | 1. liu x, wang q, yang g, et al. a novel kinase inhibitor, incb28060, blocks c-met-dependent signaling, neoplastic activities, and cross-talk with egfr and her-3. clinical cancer research : an official journal of the american association for cancer research. 2011;17(22):7127-7138. |
| | Capmatinib Preparation Products And Raw materials |
|